Literature DB >> 20409584

Decrease of CD4(+)CD25(+) regulatory T cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation.

Qing Li1, Zhimin Zhai, Xiucai Xu, Yuanyuan Shen, Aimei Zhang, Zimin Sun, Huilan Liu, Liangquan Geng, Yiping Wang.   

Abstract

Graft-versus-host disease (GVHD) is a frequent and life threatening complication of allogeneic haematogenesis stem cell transplantation (aHSCT). The correlation of CD4(+)CD25(+) regulatory T cells (Tregs) in the patients after aHSCT to the occurrence and severity of acute and chronic GVHD (aGVHD and cGVHD) is not fully investigated. Here, we examined the levels of CD4(+)CD25(+) Tregs by assessment of CD4(+)CD25(high) and CD4(+)CD25(+)CD127(low) in peripheral blood, and the levels of serum TGF-beta and TNF-alpha in 56 patients at early immune reconstitution following aHSCT. Our data showed a significant reduction in the frequency of Tregs in patients with grades II-IV aGVHD and extensive cGVHD compared to healthy controls. Moreover, a decreased level of CD4(+)CD25(+) Tregs was correlated to increased severity of GVHD. The levels of CD4(+)CD25(+) Tregs in non-GVHD groups were however significantly higher than that in healthy controls. A significant decrease in the levels of TGF-beta and a significant increase the levels of TNF-alpha was also seen with increased severity of GVHD. This study suggested that measurement of CD4(+)CD25(+) Tregs along with serum TGF-beta and TNF-alpha at early immune reconstruction after aHSCT may indicate the onset and severity of both aGVHD and cGVHD. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20409584     DOI: 10.1016/j.leukres.2010.03.017

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  34 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

2.  Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease.

Authors:  Jennifer L Lockridge; Ying Zhou; Yusof A Becker; Shidong Ma; Shannon C Kenney; Peiman Hematti; Christian M Capitini; William J Burlingham; Annette Gendron-Fitzpatrick; Jenny E Gumperz
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-24       Impact factor: 5.742

3.  Increased Th17/Treg ratio in chronic liver GVHD.

Authors:  F Malard; C Bossard; E Brissot; P Chevallier; T Guillaume; J Delaunay; J-F Mosnier; P Moreau; M Grégoire; B Gaugler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 4.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

Review 5.  Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.

Authors:  Michael R Verneris
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.

Authors:  Hemn Mohammadpour; Rachel O'Neil; Jingxin Qiu; Philip L McCarthy; Elizabeth A Repasky; Xuefang Cao
Journal:  J Immunol       Date:  2018-02-14       Impact factor: 5.422

Review 7.  Therapeutic use of regulatory T cells for graft-versus-host disease.

Authors:  Shlomo Elias; Alexander Y Rudensky
Journal:  Br J Haematol       Date:  2019-08-16       Impact factor: 6.998

8.  Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.

Authors:  Yutaka Kawano; Haesook T Kim; Ken-Ichi Matsuoka; Gregory Bascug; Sean McDonough; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2011-09-07       Impact factor: 22.113

Review 9.  Biologic markers of chronic GVHD.

Authors:  J Pidala; M Sarwal; S Roedder; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-07-22       Impact factor: 5.483

10.  Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation.

Authors:  Matthew Horch; Vu H Nguyen
Journal:  Ther Adv Hematol       Date:  2012-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.